Amgen Inc (AMGN)vsSony Group Corp (SONY)
AMGN
Amgen Inc
$331.70
+0.79%
HEALTHCARE · Cap: $177.71B
SONY
Sony Group Corp
$20.15
+1.31%
TECHNOLOGY · Cap: $122.47B
Smart Verdict
WallStSmart Research — data-driven comparison
Sony Group Corp generates 35285% more annual revenue ($13.17T vs $37.22B). AMGN leads profitability with a 21.0% profit margin vs -1.6%. AMGN appears more attractively valued with a PEG of 2.18. AMGN earns a higher WallStSmart Score of 62/100 (C+).
AMGN
Buy62
out of 100
Grade: C+
SONY
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.2%
Fair Value
$321.89
Current Price
$331.70
$9.81 premium
Intrinsic value data unavailable for SONY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 101 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Generating 898.5B in free cash flow
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Trading at 19.5x book value
4.4% earnings growth
0.5% revenue growth
Expensive relative to growth rate
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bull Case : SONY
The strongest argument for SONY centers on Free Cash Flow, Market Cap, P/E Ratio.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.
Bear Case : SONY
The primary concerns for SONY are Revenue Growth, PEG Ratio, Profit Margin.
Key Dynamics to Monitor
AMGN profiles as a mature stock while SONY is a turnaround play — different risk/reward profiles.
SONY carries more volatility with a beta of 0.72 — expect wider price swings.
AMGN is growing revenue faster at 5.8% — sustainability is the question.
SONY generates stronger free cash flow (898.5B), providing more financial flexibility.
Bottom Line
AMGN scores higher overall (62/100 vs 47/100), backed by strong 21.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Sony Group Corp
TECHNOLOGY · CONSUMER ELECTRONICS · USA
Sony Group Corporation designs, develops, produces and sells electronic equipment, instruments and devices for the consumer, professional and industrial markets worldwide. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?